Author + information
- Valeria Paradies1,
- Georgios Vlachojannis2,
- Kees-Jan Royaards3,
- Jochem Wassing4,
- Martin van der Ent5 and
- Pieter Smits5
Bioresorbable vascular scaffolds (BVS) are increasingly being used for bifurcation treatments but data on angiographic and clinical outcomes is scarce.
Data were examined of 107 patients with at least one coronary bifurcation lesion involving a side-branch (SB) ≥ 2mm. Angiographic and clinical outcomes were collected. Optical coherence tomography analysis was performed in a subgroup of patients.
Between July 2009 and December 2015, 423 patients underwent PCI with Absorb BVS. A total of 110 lesions were identified as bifurcations, of whom 24.5% were classified as true bifurcation lesions. Lesion complexity B2/C was 68.1%. Procedural success of main branch was 100% while SB impairment at the end of the procedure was 4.5%. The mean follow-up was 21 months with one third of the patients followed up for at least 2 years. The overall TLF and ST rate at 1 year was 7.8% and 3.9%, respectively.
|CLINICAL OUTCOMES (1 year follow-up)||Patients (n:101)|
|Death, % (n)||6.9 (7)|
|Cardiac Death, % (n)||0.9 (1)|
|MI, % (n)||4.9 (5)|
|TLR, % (n)||4.9 (5)|
|TVR, % (n)||6.9 (7)|
|Target lesion failure, % (n)||7.9 (8)|
|Def ST, % (n) Acute Subacute Late||3.9 (4) 1 (0.9) 2 (1.9) 1 (0.9)|
|Prob ST, % (n)||0.9 (1)|
|Poss ST, % (n)||0.0 (0)|
The results of the present analysis suggest the BVS implanted in bifurcations lesions are associated with procedural safety and angiographic success as well as acceptable TLF rate at 1 year. However the higher ST rates, compared to contemporary drug eluting stents, support the importance of careful lesions selection and meticulous implantation technique.
CORONARY: Bioresorbable Vascular Scaffolds